{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:42:12Z","timestamp":1791765732616,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.transci.2020.102965","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T13:33:14Z","timestamp":1603114394000},"page":"102965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Low rates of anti-recipient isohemagglutinins in ABO incompatible hematopoietic stem cell transplants"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9480-2762","authenticated-orcid":false,"given":"Brian D.","family":"Adkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deva","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adetola A.","family":"Kassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Eichbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2020.102965_bib0005","series-title":"Transfusion Medicine and Hemostasis","author":"Savage","year":"2013"},{"key":"10.1016\/j.transci.2020.102965_bib0010","series-title":"Technical Manual","author":"Westman","year":"2020"},{"key":"10.1016\/j.transci.2020.102965_bib0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.21307\/immunohematology-2019-231","article-title":"The ABO blood group system revisited: a review and update","volume":"25","author":"Storry","year":"2009","journal-title":"Immunohematology"},{"key":"10.1016\/j.transci.2020.102965_bib0020","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/genetics\/155.3.995","article-title":"the First Human Marker Locus","volume":"155","author":"Karl Landsteiner","year":"2000","journal-title":"Genetics"},{"issue":"Suppl 2","key":"10.1016\/j.transci.2020.102965_bib0025","first-page":"S74","article-title":"Anti-A and anti-B: what are they and where do they come from?","volume":"55","author":"Branch","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2020.102965_bib0030","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/bmt.2012.32","article-title":"Anti-host isohemagglutinin production is associated with a higher risk of acute GVHD in ABO-incompatible transplantation","volume":"47","author":"Igarashi","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2020.102965_bib0035","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bbmt.2017.02.009","article-title":"Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source","volume":"23","author":"Damodar","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2020.102965_bib0040","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.bbmt.2013.03.018","article-title":"Clinical Guide to ABO-Incompatible Allogeneic Stem Cell Transplantation","volume":"19","author":"Booth","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2020.102965_bib0045","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1182\/blood.V128.22.3394.3394","article-title":"Impact of ABO Incompatibility on Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation","volume":"128","author":"Prokopchuk-Gauk","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.transci.2020.102965_bib0050","article-title":"Impact of ABO blood group incompatibility on the outcomes of allogeneic hematopoietic stem cell transplantation","author":"Ciftciler","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2020.102965_bib0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000441507","article-title":"ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation","volume":"43","author":"Worel","year":"2016","journal-title":"Transfus Med Hemotherapy"},{"key":"10.1016\/j.transci.2020.102965_bib0060","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.bmt.1703621","article-title":"Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation","volume":"30","author":"Stussi","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2020.102965_bib0065","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12185-013-1360-6","article-title":"IgM anti-recipient ABO antibodies predict acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation","volume":"98","author":"Zaimoku","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.transci.2020.102965_bib0070","first-page":"124","article-title":"Evaluation of Blood Group Conversion Following ABO-Incompatible Hematopoietic Stem Cell Transplantation (HCT)","author":"Chan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.transci.2020.102965_bib0075","first-page":"699","article-title":"CHANGES IN DONORS' ISOAGGLUTININS AGAINST RECIPIENTS' RED CELLS IN MINOR OR BIDIRECTIONAL ABO-INCOMPATIBLE HEMATOPOIETIC STEM CELL TRANSPLANTATION","volume":"62","author":"Abe","year":"2016","journal-title":"Japanese J Transfus Cell Ther"},{"key":"10.1016\/j.transci.2020.102965_bib0080","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1046\/j.1365-2141.2003.04128.x","article-title":"Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation","volume":"120","author":"Lee","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2020.102965_bib0085","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.transproceed.2004.12.281","article-title":"Levels of Anti-A\/B Antibodies After ABO-Incompatible Hematopoietic Stem Cell Transplantation","volume":"37","author":"Stussi","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transci.2020.102965_bib0090","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/tme.12386","article-title":"Isohaemagglutinin production after minor ABO incompatible umbilical cord blood transplantation","volume":"27","author":"Solves","year":"2017","journal-title":"Transfus Med"},{"key":"10.1016\/j.transci.2020.102965_bib0095","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/sj.bmt.1705409","article-title":"Lack of isohemagglutinin production following minor ABO incompatible unrelated HLA mismatched umbilical cord blood transplantation","volume":"38","author":"Snell","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2020.102965_bib0100","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","article-title":"IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade","volume":"97","author":"Rowlings","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2020.102965_bib0105","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJM197504242921706","article-title":"Bone-marrow transplantation (second of two parts)","volume":"292","author":"Thomas","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2020.102965_bib0110","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1182\/blood.V86.2.813.bloodjournal862813","article-title":"Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation","volume":"86","author":"Gratwohl","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.transci.2020.102965_bib0115","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1182\/asheducation-2015.1.378","article-title":"Management of hemolytic anemia following allogeneic stem cell transplantation","volume":"2015","author":"Holbro","year":"2015","journal-title":"Hematology"},{"key":"10.1016\/j.transci.2020.102965_bib0120","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1537-2995.2011.03069.x","article-title":"How do I approach ABO-incompatible hematopoietic progenitor cell transplantation? (CME)","volume":"51","author":"Daniel-Johnson","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2020.102965_bib0125","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3389\/fimmu.2019.00309","article-title":"Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease","volume":"10","author":"Thangavelu","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.transci.2020.102965_bib0130","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","article-title":"Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide","volume":"98","author":"Luznik","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.transci.2020.102965_bib0135","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0171-2985(96)80033-7","article-title":"Cyclophosphamide-induced immunological tolerance: an overview","volume":"195","author":"Mayumi","year":"1996","journal-title":"Immunobiology"},{"key":"10.1016\/j.transci.2020.102965_bib0140","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3389\/fimmu.2019.01342","article-title":"Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation","volume":"10","author":"Bertaina","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.transci.2020.102965_bib0145","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1537-2995.2011.03465.x","article-title":"Recommendations for transfusion in ABO-incompatible hematopoietic stem cell transplantation","volume":"52","author":"O\u2019Donghaile","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2020.102965_bib0150","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/sj.bmt.1702572","article-title":"Transplantation of ABO-incompatible bone marrow and peripheral blood stem cell components","volume":"26","author":"Rowley","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2020.102965_bib0155","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.bbmt.2009.07.002","article-title":"Minor ABO-mismatches are risk factors for acute graft-versus-host disease in hematopoietic stem cell transplant patients","volume":"15","author":"Ludajic","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2020.102965_bib0160","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1053\/bbmt.2001.v7.pm11760150","article-title":"Analysis of risk factor for the development of GVHD after T cell-depleted allogeneic BMT: Effect of HLA disparity, ABO incompatibility, and method of T-cell depletion","volume":"7","author":"Keever-Taylor","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2020.102965_bib0165","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21307\/immunohematology-2019-004","article-title":"Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation","volume":"33","author":"Cooling","year":"2017","journal-title":"Immunohematology"},{"key":"10.1016\/j.transci.2020.102965_bib0170","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-065X.2011.01019.x","article-title":"Mechanisms of tolerance","volume":"241","author":"Bluestone","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.transci.2020.102965_bib0175","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050220302810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050220302810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:53:22Z","timestamp":1761468802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050220302810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1473050220302810"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2020.102965","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low rates of anti-recipient isohemagglutinins in ABO incompatible hematopoietic stem cell transplants","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2020.102965","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102965"}}